AKT1 and metastatic prostate carcinoma: After a median follow-up of 19 months, the inhibition of PI3K/AKT and androgen-receptor dual pathways by ipatasertib (an ATP-competitive AKT inhibitor) plus abiraterone can improve the median radiographical progression-free survival of metastatic prostate cancer patients with PTEN loss compared with placebo plus abiraterone (18·5 months vs. 16·5 months) in the IPATential150 trial.